Indianapolis, Indiana – Eli Lilly and Novo Nordisk have emerged as key players in the pharmaceutical industry, driving investor interest with their blockbuster GLP-1 drugs for treating obesity. Over the past year, shares of Eli Lilly have surged by 72%, with Novo Nordisk not far behind with a 44% increase. Novo Nordisk stands as the largest company in Europe by market cap, while Eli Lilly holds the eighth spot among US companies with a market cap of $900 billion.
Investors have been drawn to both companies due to promising research indicating potential expanded medical indications beyond weight loss and diabetes treatment. This optimism has led investors to seek out the next big breakthrough in the pharmaceutical sector.
Viking Therapeutics, a biotechnology firm, has captured the attention of investors, with RSE Ventures CEO Matt Higgins touting its potential on a recent segment of “Good Buy or Goodbye.” Higgins highlighted Viking’s innovative products, including a monthly shot and a pill, which have shown promising early results and strong tolerability.
Despite Viking’s lack of revenue and smaller workforce compared to industry giants like Eli Lilly and Novo Nordisk, the company’s stock has soared by nearly 250% this year. With a market cap of $7 billion, Viking’s potential for growth and development in the pharmaceutical space is attracting investors looking for the next big opportunity.
Higgins predicts that Viking’s shares remain attractive, citing the possibility of acquisition and an upcoming conference in November where the company is expected to share new findings on its GLP-1 drugs. With a potential takeout value of $15 billion and exciting developments on the horizon, Viking Therapeutics continues to pique investor interest in the ever-evolving pharmaceutical landscape.